6833 Stock Overview
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Sinco Pharmaceuticals Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.33 |
| 52 Week High | HK$1.65 |
| 52 Week Low | HK$0.18 |
| Beta | 0.56 |
| 1 Month Change | -13.16% |
| 3 Month Change | -17.50% |
| 1 Year Change | -79.11% |
| 3 Year Change | 50.00% |
| 5 Year Change | -26.67% |
| Change since IPO | -58.75% |
Recent News & Updates
Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?
May 30
Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet
Oct 26Recent updates
Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?
May 30Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet
Oct 26Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today
Feb 04I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease
Oct 25Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings
Jun 10Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt
May 24Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock
Apr 20We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings
Feb 16How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 11
Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?
Dec 07Shareholder Returns
| 6833 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | -2.9% | 0.6% | 3.8% |
| 1Y | -79.1% | -44.5% | -11.0% |
Return vs Industry: 6833 underperformed the Hong Kong Healthcare industry which returned -44.5% over the past year.
Return vs Market: 6833 underperformed the Hong Kong Market which returned -11% over the past year.
Price Volatility
| 6833 volatility | |
|---|---|
| 6833 Average Weekly Movement | 7.0% |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in HK Market | 13.0% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 6833 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 6833's weekly volatility has decreased from 16% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 231 | Min Jin | https://www.sinco-pharm.com |
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers Octapharma, a human albumin solution for use in premature infants; Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections; and Medocef that is used for the treatment of bacterial infections, such as the infections of the lower respiratory tract comprising pneumonia, urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and sepsis. It also provides Esafosfina, which is used for treating hypophosphatemia and chronic diseases, which include alcohol intoxication, malnutrition, and hypophosphatemic respiratory failure; Taurolite, a third generation oral cholic acid drug that is used for the treatment of gallstone diseases; and Tamifil injection for the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis.
Sinco Pharmaceuticals Holdings Limited Fundamentals Summary
| 6833 fundamental statistics | |
|---|---|
| Market Cap | HK$681.02m |
| Earnings (TTM) | HK$76.26m |
| Revenue (TTM) | HK$2.49b |
8.8x
P/E Ratio0.3x
P/S RatioIs 6833 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6833 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.27b |
| Cost of Revenue | CN¥1.97b |
| Gross Profit | CN¥305.87m |
| Other Expenses | CN¥236.41m |
| Earnings | CN¥69.46m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.034 |
| Gross Margin | 13.47% |
| Net Profit Margin | 3.06% |
| Debt/Equity Ratio | 30.1% |
How did 6833 perform over the long term?
See historical performance and comparison